|
[1]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
|
|
[2]WITKOWSKI ER,SMITH JK,TSENG JF.Outcomes following resection of pancreatic cancer[J].J Surg Oncol,2013,107(1):97-103.
|
|
[3]NEOPTOLEMOS JP,STOCKEN DD,FRIESS H,et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J].N Engl J Med,2004,350(12):1200-1210.
|
|
[4]STOCKEN DD,BUCHLER MW,DERVENIS C,et al.Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer[J].Br J Cancer,2005,92(8):1372-1381.
|
|
[5]KALSER MH,ELLENBERG SS.Pancreatic cancer.Adjuvant combined radiation and chemotherapy following curative resection[J].Arch Surg,1985,120(8):899-903.
|
|
[6]BURRIS HA 3rd,MOORE MJ,ANDERSEN J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
|
|
[7]JAVLE M,HSUEH CT.Updates in Gastrointestinal Oncology insights from the 2008 44th annual meeting of the American Society of Clinical Oncology[J].J Hematol Oncol,2009,2:9.
|
|
[8]OETTLE H,NEUHAUS P,HOCHHAUS A,et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer:the CONKO-001 randomized trial[J].JAMA,2013,310(14):1473-1481.
|
|
[9]MAEDA A,BOKU N,FUKUTOMI A,et al.Randomized phaseⅢtrial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer:Japan Adjuvant Study Group of Pancreatic Cancer(JASPAC-01)[J].Jpn J Clin Oncol,2008,38(3):227-229.
|
|
[10]The Chinese Society of Clinical Oncology Pancreatic Cancer Expert Committee.Chinese consensus on pancreatic cancer diagnosis and treatment(2014 version)[J].J Clin Hepatol,2014,30(10):970-980.(in Chinese)中国临床肿瘤学会胰腺癌专家委员会.胰腺癌综合诊治中国专家共识(2014年版)[J].临床肝胆病杂志,2014,30(10):970-980.
|
|
[11]PALMER DH,STOCKEN DD,HEWITT H,et al.A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer:gemcitabine alone versus gemcitabine combined with cisplatin[J].Ann Surg Oncol,2007,14(7):2088-2096.
|
|
[12]National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:pancreatic adenocarcinoma(Version 2.2016)[EB/OL].https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
|
|
[13]BIDARD FC,HUGUET F,LOUVET C,et al.Circulating tumor cells in locally advanced pancreatic adenocarcinoma:the ancillary Cir Ce 07study to the LAP 07 trial[J].Ann Oncol,2013,24(8):2057-2061.
|
|
[14]von HOFF DD,ERVIN T,ARENA FP,et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J].N Engl J Med,2013,369(18):1691-1703.
|
|
[15]CONROY T,DESSEIGNE F,YCHOU M,et al.FOLFIRINOXversus gemcitabine for metastatic pancreatic cancer[J].N Engl JMed,2011,364(19):1817-1825.
|
|
[16]MOORE MJ,GOLDSTEIN D,HAMM J,et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(15):1960-1966.
|
|
[17]STRUMBERG D,SCHULTHEIS B,EBERT MP,et al.PhaseⅡ,randomized,double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients(pts)with advanced pancreatic cancer(PC)[C].ASCO Annual Meeting,2013.
|
|
[18]KO AH,TEMPERO MA,SHAN YS,et al.A multinational phase2 study of nanoliposomal irinotecan sucrosofate(PEP02,MM-398)for patients with gemcitabine-refractory metastatic pancreatic cancer[J].Br J Cancer,2013,109(4):920-925.
|
|
[19]WANG-GILLAM A,LI CP,BODOKY G,et al.Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy(NAPOLI-1):a global,randomised,open-label,phase 3 trial[J].Lancet,2016,387(10018):545-557.
|
DownLoad: